Drug-related pulmonary toxicity in non-Hodgkin's lymphoma. Comparative results with three different treatment regimens

Cancer. 1991 Aug 15;68(4):699-705. doi: 10.1002/1097-0142(19910815)68:4<699::aid-cncr2820680406>3.0.co;2-5.

Abstract

Pulmonary toxicity may complicate the treatment of non-Hodgkin's lymphoma (NHL). The possible drug-related cause of pulmonary toxicity was investigated retrospectively in 207 NHL patients treated between 1981 and 1988 with three regimens containing cyclophosphamide with and without methotrexate or bleomycin: methotrexate, calcium, leucovorin, bleomycin, doxorubicin, cyclophosphamide, vincristine, and dexamethasone (m-BACOD) (n = 134); methotrexate, calcium, leucovorin, doxorubicin, cyclophosphamide, vincristine, and dexamethasone (m-ACOD) (n = 43); or cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) (n = 30) chemotherapy. These regimens contained the same drugs and were administered in the same schedule; the regimens differed primarily in the addition of bleomycin or methotrexate. Pulmonary toxicity occurred in 24 of 134 (18%) m-BACOD-treated and in six of 43 (14%) m-ACOD-treated patients (P = 0.65). Chest radiography revealed diffuse pulmonary infiltrates in 16 (67%) and six (100%) of the m-BACOD-treated and m-ACOD-treated patients with pulmonary toxicity, respectively. None of the CHOP-treated patients had pulmonary toxicity. The clinical features of pulmonary toxicity and the amount of chemotherapy administered before it occurred did not differ in patients treated with m-BACOD or m-ACOD, although the toxicity tended to be more severe in the m-BACOD group. Open lung or transbronchial biopsies done in six (38%) of the m-BACOD-treated and three (50%) of the m-ACOD-treated patients with pulmonary infiltrates revealed nonspecific pneumonitis compatible with drug-related toxicity. In summary, these results showed that pulmonary toxicity during m-BACOD and m-ACOD therapy occurred with similar frequency and clinicopathologic features. This suggested that bleomycin was not responsible uniquely for the pulmonary toxicity in m-BACOD-treated patients. That pulmonary toxicity was not observed in patients treated with CHOP suggested that methotrexate may play an important role in the pathogenesis of the pulmonary toxicity.

Publication types

  • Comparative Study

MeSH terms

  • Adult
  • Antineoplastic Combined Chemotherapy Protocols / adverse effects*
  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use
  • Bleomycin / administration & dosage
  • Calcium / administration & dosage
  • Cyclophosphamide / administration & dosage
  • Dexamethasone / administration & dosage
  • Doxorubicin / administration & dosage
  • Female
  • Humans
  • Leucovorin / administration & dosage
  • Lung Diseases / chemically induced*
  • Lung Diseases / diagnostic imaging
  • Lung Diseases / drug therapy
  • Lung Diseases / pathology
  • Lymphoma, Non-Hodgkin / drug therapy*
  • Male
  • Methotrexate / administration & dosage
  • Middle Aged
  • Prednisone / administration & dosage
  • Radiography
  • Retrospective Studies
  • Trimethoprim, Sulfamethoxazole Drug Combination / therapeutic use
  • Vincristine / administration & dosage

Substances

  • Bleomycin
  • Vincristine
  • Dexamethasone
  • Doxorubicin
  • Trimethoprim, Sulfamethoxazole Drug Combination
  • Cyclophosphamide
  • Leucovorin
  • Calcium
  • Prednisone
  • Methotrexate

Supplementary concepts

  • CHOP protocol
  • M-BACOD protocol
  • m-ACOD protocol